Project Grant R21AI182967

Award Date 6/17/24
Completion Date 4/30/26
Dollars Obligated $1M
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92037, USA
Similar Awards
This $1,200,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports research to elucidate the mechanism of cytokine activation and delineate the spatiotemporal regulation of inflammasomes. The goal is to build a spatiotemporal map of inflammasome formation and signaling to provide key mechanistic insights to aid therapeutic development for immune-related disorders. The award recipient is...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $737,502 to The Washington University in St. Louis to investigate the role of the WDFY4 protein in regulating antigen presentation by dendritic cells and the development of regulatory T cells. The research aims to: 1) determine the impact of WDFY4 on the T cell receptor repertoire, particularly in regulatory T cells;...
This $1,002,148 federal Project Grant award, funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to understand the role of autophagy, a cellular mechanism for clearing damaged organelles and harmful materials, in neurological diseases like Parkinson's, Alzheimer's, and ALS. The research aims to determine how the regulation of...
This $410,000 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research to uncover the mechanisms behind amylopectinosis, a condition characterized by the formation of insoluble polyglucosan bodies, in the context of Linear Ubiquitin Chain Assembly Complex (LUBAC) deficiency. The research aims to utilize newly developed mouse...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) totaling $373,375 will support research to understand the interactions between ultra-small nanoparticles (USNPs) and inflammatory monocytes, and how these interactions can be leveraged to target inflammation. The research aims to: 1) determine the fundamental mechanisms governing USNP-inflammatory monocyte interactions, including how the USNP...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides approximately $2.4 million over 3 years to the Benaroya Research Institute at Virginia Mason to investigate how genetic variants impact the function of pathogenic T cells in inflammatory bowel diseases (IBDs). The key research activities involve: Performing massively parallel...
This $707,534 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research at Pennsylvania State University's Milton S. Hershey Medical Center focused on understanding the role of the ZFAND6 protein in regulating mitophagy, inflammation, and the NLRP3 inflammasome. The primary goals are to determine the mechanisms by which ZFAND6 regulates these cellular processes, with...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to investigate the role of the LRRK2-G2019S genetic variant in promoting necroptotic cell death and inflammation in macrophages. The $162,000 award to Tulane University will support research to uncover how this Parkinson's disease-associated variant can reprogram innate immune pathways and cell death modalities,...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $506,394.00 in funding to the University of Chicago to conduct research on bacterial cholesterol-dependent cytolysins (CDCs) and their role in activating the NLRP3 inflammasome. The research aims to define the molecular and cellular mechanisms by which CDCs can remodel host organelles to stimulate the NLRP3...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $195,894.00 to The Washington University to study the mechanisms contributing to T cell dysregulation in STAT3 gain-of-function (GOF) syndrome. The primary scientific goal is to investigate critical interactions between T and B cells, as well as the development, polarization, and function of these cells, in order to...

MECHANISTIC INVESTIGATION OF THE ROLE OF FBXW7 IN INFLAMMASOME ACTIVATION - THE NLRP3 INFLAMMASOME IS A KEY REGULATOR OF INFLAMMATORY RESPONSES. THESE INCLUDE RESPONSES TO INFECTION BY PATHOGENS BUT ALSO ARE A COMPONENT OF MANY CHRONIC INFLAMMATORY DISEASES, INCLUDING NEURODEGENERATIVE DISEASES. THE END POINT OF THE INFLAMMASOME RESPONSE IS THE SECRETION OF MATURE INFLAMMATORY CYTOKINES, IL-1B AND IL-18. TO ACCOMPLISH THIS, THE NLRP3 INFLAMMASOME IS ASSEMBLED AND ACTIVATED THROUGH A COMPLEX SERIES OF EVENTS, SOME OF WHICH REMAIN POORLY UNDERSTOOD. THE FIRST STEP IN NLRP3 INFLAMMASOME ACTIVATION IS THE DE NOVO BIOSYNTHESIS OF NLRP3 ITSELF THROUGH TRANSCRIPTIONAL UPREGULATION, AND THE ASSEMBLY OR NEWLY SYNTHESIZED NLRP3 MOLECULES INTO INACTIVE OLIGOMERS. HOW THIS OCCURS IS ONLY PARTIALLY UNDERSTOOD. WE HAVE EVIDENCE THAT THE UBIQUITIN LIGASE SCFFBXW7 IS REQUIRED FOR THIS PARTICULAR PROCESS. THE OBJECTIVE OF THE PROPOSED RESEARCH IS TO TEST A HYPOTHESIS WHERE SCFFBXW7 PLACES UBIQUITIN CHAINS ON THE N-TERMINAL END OF NLRP3 WHICH ARE BOUND AND CAPPED BY A UIM (UBIQUITIN INTERACTING MOTIF) NEAR THE C-TERMINUS. THE CONSTRAINTS ENFORCED BY THIS INTERACTION WOULD LOCK NLRP3 IN A CONFORMATION THAT WOULD PROMOTE THE ASSEMBLY OF INACTIVE OLIGOMERS.

Posted 6/17/24, 12:00 AM